Articles related to CLINICAL STUDY

Recordings from four Parkinson’s disease patients linked cuneiform and pedunculopontine nuclei activity to distinct phases of gait initiation. Freezing episodes were preceded by disrupted mesencephalic timing, though clinical translation remains early.

The NAUTILUS trial met its primary safety endpoint for responsive centromedian thalamic stimulation in drug-resistant idiopathic generalized epilepsy. The prespecified primary effectiveness endpoint was not significant, while post hoc and 18-month outcomes showed sustained seizure reductions.

In a 3-year randomized clinical trial, dialectical behavior therapy and schema therapy produced substantial improvements in borderline personality disorder severity. No statistically significant differences were observed between treatments on primary or secondary outcomes.

Fluvoxamine reduced fatigue and improved quality-of-life measures in adults with long COVID in a randomized placebo-controlled trial. The findings provide evidence for a potential therapy, although further research is needed to define optimal patient selection and treatment strategies.

The FDA approved centanafadine for ADHD in adults and children aged 6 years and older, introducing the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for the disorder. Approval was based on phase 3 trial results and regulatory review.

Individuals with psychiatric disorders demonstrated reduced flexibility in brain network reconfiguration across cognitive states in a transdiagnostic neuroimaging study. The findings linked dynamic brain patterns with symptom profiles but did not establish causality or clinical applicability.